Evidence map›Paper›PMID 27998306›Full record

ArticleJournal of medical case reports2016

Intramammary metastatic melanoma of unknown primary origin in a 58-year old patient: a case report.

Zeina El-Tani, Christophe Duc, Thomas Gluecker, Olivier Cottier

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of medical case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Zeina El-TaniService de Gynécologie-Obstétrique, HRC (Hôpital Riviera-Chablais), Aigle, Switzerland. zeinae@gmail.com.
Christophe DucInstitut d'Histocytopathologie, ICHV, Sion, Switzerland.
Thomas GlueckerService de Radiodiagnostic et de Radiologie, HRC Suisse, Aigle, Switzerland.
Olivier CottierService de Gynécologie-Obstétrique, HRC (Hôpital Riviera-Chablais), Aigle, Switzerland. Olivier.Cottier@hopitalrivierachablais.ch.
Hôpital Riviera-Chablais · CHInstitut de Recherche en Opthalmologie · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant melanoma metastasis to the breast is a rare disease. CASE PRESENTATION: We present the case of a 58-year-old postmenopausal Caucasian woman with metastatic malignant melanoma of unknown origin of the right breast. She presented with a palpable lump in the inferior quadrant of her right breast. The investigations concluded it was breast metastasis from a malignant melanoma of unknown origin. The treatment consisted of mastectomy and axillary lymph node dissection. Two lymph nodes were positive for tumor cells and one showed extracapsular extension. Our patient did not receive immediate adjuvant therapy. Six weeks after the surgery, our patient presented a relapse in the right axilla (a 6 × 4 cm mass) with positive internal mammary lymph nodes and a single brain metastasis. This relapse motivated an adjuvant treatment with partial regression of the disease. Currently, our patient presents multiple metastases with poor prognosis.

conclusionsFrom this experience, we advocate an immediate aggressive handling of melanoma metastasis to the breast.

Indexed as

MastectomyAxillaBrain NeoplasmsBreast NeoplasmsCombined Modality TherapyCutaneous Malignant MelanomaFemaleHumansLymphatic IrradiationLymphatic MetastasisMelanomaMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Unknown PrimaryPrognosisSkin NeoplasmsBreast cancerDiagnosisMelanomaMetastaticTherapy

Identifiers

PMID27998306
PMCPMC5175386
OpenAlexW2565299616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.